Gautschi O P, Cadosch D, Collen T D, Land M, Hoederath P, Hildebrandt G, Fournier J-Y, Hundsberger T
Klinik für Neurochirurgie, Kantonsspital St. Gallen, Rorschacher Strasse 95, St. Gallen.
Praxis (Bern 1994). 2010 Mar 3;99(5):295-308. doi: 10.1024/1661-8157/a000052.
Glioblastoma multiforme (GBM) is the most frequently encountered malignant cerebral tumor. Despite significant improvements in the treatment of GBM, this disease remains associated with a high morbidity and mortality, with more than half of all affected patients dying within the first year after diagnosis. Typical symptoms include focal neurological symptoms, seizures, personality changes and neurocognitive symptoms. GBM can be identified by means of cerebral imaging modalities and subsequently confirmed histopathologically through biopsy or resection. At present, surgical resection followed by radiotherapy with concomitant chemotherapy with temozolomide and subsequent adjuvant chemotherapy with temozolomide is considered the standard therapy for patients with GBM. Currently, many interdisciplinary studies with glioblastoma patients are accomplished with the aim to further improve the prognosis of the affected patients.
多形性胶质母细胞瘤（GBM）是最常见的恶性脑肿瘤。尽管GBM的治疗有了显著改善，但这种疾病的发病率和死亡率仍然很高，超过一半的患者在诊断后的第一年内死亡。典型症状包括局灶性神经症状、癫痫发作、人格改变和神经认知症状。GBM可通过脑部成像手段识别，随后通过活检或切除进行组织病理学确诊。目前，手术切除后进行放疗并同步使用替莫唑胺化疗，随后进行替莫唑胺辅助化疗，被认为是GBM患者的标准治疗方法。目前，许多针对胶质母细胞瘤患者的跨学科研究正在进行，目的是进一步改善患者的预后。
